Drug
Etirinotecan pegol clinical trials
Also written NKTR-102.
- studies test it
- 10
- open now
- 0
- in phase 3
- 2
- first study started
- 2008
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
10 studies that test it; most in 2008 (4)
| Year | Studies |
|---|---|
| 2008 | 4 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 7
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 2
Nektar Therapeutics (8) · Abramson Cancer Center at Penn Medicine (1) · Lawrence Recht (1)
Studies
Open first, then newest update. How each study uses etirinotecan pegol is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and CapecitabineCompletedPhase 3Nektar TherapeuticsNCT02915744Written as NKTR-102
- An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 StudiesCompletedPhase 2Nektar TherapeuticsNCT01457118Written as NKTR-102 145 mg/m2
- NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal CancerCompletedPhase 2Nektar TherapeuticsNCT00856375Written as NKTR-102
- NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)CompletedPhase 2Nektar TherapeuticsNCT00598975Written as NKTR-102 100 mg/m2
- Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian CancerCompletedPhase 2Nektar TherapeuticsNCT00806156Written as NKTR-102 q14d
- The BEACON Study (Breast Cancer Outcomes With NKTR-102)CompletedPhase 3Nektar TherapeuticsNCT01492101Written as NKTR-102
- Etirinotecan Pegol (NKTR-102) in NSCLCCompletedPhase 2Abramson Cancer Center at Penn MedicineNCT01773109Written as Etirinotecan pegol (NKTR-102)
- Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast CancerCompletedPhase 2Nektar TherapeuticsNCT00802945Written as NKTR-102
- A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and SafetyCompletedPhase 1Nektar TherapeuticsNCT01976143Written as NKTR-102
- Phase II NKTR-102 In Bevacizumab-Resistant High Grade GliomaCompletedPhase 2Lawrence RechtNCT01663012Written as Etirinotecan pegol
Codes
What other systems call etirinotecan pegol · ClinicalTrials.gg INT006297
- MeSH (NLM) C581703etirinotecan pegolConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) LJ16641SFTETIRINOTECAN PEGOLConfirmed FDA, NLM
- NCI Thesaurus C74069Etirinotecan PegolOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C581703 | etirinotecan pegol | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | LJ16641SFT | ETIRINOTECAN PEGOL | Confirmed FDA, NLM |
| NCI Thesaurus | C74069 | Etirinotecan Pegol | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.